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THERMALLY RESPONSIVE NANOSPHERES WITH DUAL DRUG RELEASE PROFILES
FOR COMBINED CRYOTHERAPY OF OSTEOARTHRITIS
Se-Young Jeong, Mi-Lan Kang, Ji-Eun Kim, Gun-Il Im
Dongguk University, Ilsan Hospital, South Korea
Introduction: In this study, diclofenac (DCF) and kartogenin (KGN) were chosen as the
combined osteoarthritis (OA) cryotherapy to induce anti-inflammatory activity and
cartilage regeneration. Here, we designed a dual drug delivery system with thermo-
responsiveness for combined therapy of OA which is composed of pluronic F127
(F127)-chitosan oligosaccharide (COS)-KGN conjugated nanospheres (F127-COS-KGN
NPs) encapsulating DCF. The aims of this study were to: (1) characterize the F127/
COS/KGNDCF for controlleddual releaseby temperature changeandF127-COS-KGNDCF;
and (2) evaluate the combined therapeutic effects of the F127-COS-KGNDCF in vitro.
Subjects andMethods: (1) Preparation of F127-COS-KGNNPs loading DCF. The F127/
COS/KGNweremade by emulsification/solvent evaporationmethod. Conjugation of
F127-COOH and KGN with COS was carried out by EDC/NHS catalysis during the NPs
synthesis process. DCF was encapsulated inside the NPs by change of wall-perme-
ability according to temperature control. (2) Controlled dual release by temperature
change. The amounts of KGN and DCF released from the NPs were determined by
HPLC chromatography. (3) In vitro chondrogenic differentiation. The hBMSC
(2.5105 cells, passage 3-5) weremade by pellets. (4) In vitro anti-inflammatory ac-
tivity. After induction of inflammationwith lipopolysaccharide (LPS), the F127/COS/
KGNDCF was used to treat the cells. (5) In vivo thermo-responsiveness & retention
time in OA joint. OA was induced surgically using ACLT and DMM in rats. After IA in-
jection of the fluorescence dye-labelled F127/COS/KGNDCF, cold temperature (5C)
were applied around the joint for 10 minutes with a cryotherapy device. Fluores-
cence spectrum was scanned using an IVIS-spectrum measurement system. (6) In
vivo cyclooxygenase inhibition. Serum and synovium were collected in OA rats after
IA injection of the F127/COS/KGNDCF. COX-2 inhibition after cold temperature treat-
mentwas evaluated by RT-qPCR and ELISA. (7) In vivo cartilage regeneration. TheOA
rats were treated with F127/COS/KGNDCF by IA injection at weeks 6 and 9 after OA
induction. The distal femora in each group were dissected at 14 weeks after OA in-
duction and evaluated by Safranin-O staining and OARSI scoring. Immunohistochem-
istry of COL2 and ACAN was also carried out.
Results: (1) Preparation of F127-COS-KGN NCs loading DCF. The F127/COS/KGN are
-300 nm at 37C and expand to w650 nm when cooled to 4C. (2) In vitro release
study. While the encapsulated DCF showed burst release for 6 hours after cold
shock, the conjugated KGN showed sustained release for 14 days even though
the temperature changed. (3) In vitro chondrogenic differentiation. The gene
expression of COL2A1 and ACAN increased in hBMSCs pellets exposed to unconju-
gated KGN and both F127/COS/KGNDCF for 21 days compared with those of un-
treated hBMSCs. (4) In vitro anti-inflammatory activity. After cold shock
treatment, the F127/COS/KGNDCF treated chondrocytes showed rapid decrease
of IL-6 secretion. (5) In vivo thermo-responsiveness & retention time in OA joint.
The fluorescence signals from F127/COS/KGNDCF were observed in the knee joint
of OA rats up to 21 days. In particular, F127/COS/KGNDCF treated rats after cold
temperature treatment showed significantly higher fluorescence intensity than
those of rats untreated with cold temperature on days 2 (p < 0.01) and 5 (p <
0.05). (6) In vivo cyclooxygenase inhibition. After cold temperature treatment,
the F127/COS/KGNDCF injected rats showed decrease of COX-2 activity.
Discussion andConclusion: Both KGNandDCFwere released independently from the
F127/COS/KGNDCF by temperature control. COX-2 inhibitionbyDCF released from the
NCs after cold temperature treatment was confirmed. The F127/COS/KGNDCF can be
effectively combined therapeutic for OA by thermally controlled dual drug delivery.
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CORRELATION ANALYSIS OF DXA AND COMBINED USE OF QUS AND OSTA
Yue Ding, Yan Zhang, Changchuan Li, Guangtao Fu, Wei Liu
The Memorial Hospital of Sun Yat-sen University, China
Background: At present, the population aging situation in China has become more
and more serious. Osteoporosis is one of the deadliest diseases that affect the
health of the elderly. Early detection and early prevention of osteoporosis can
help to avoid serious complications of osteoporosis, such as limb brittle fractures
or vertebral compression fractures. The extended life expectancy and increasing
number of elderly in the population means the arrival of an aging society. Quanti-
tative ultrasound (QUS) is a non-invasive method for evaluating bone mass density
developed in the 90s. It not only reflects the bone density, but also contributes toshow the bone strength and bone structure characteristics; therefore, it has the
value of diagnosing osteoporosis and predicting potential fracture risks as well.
At the same time it is convenient to carry and easy to operate. Asian osteoporosis
self-assessment tool (OSTA) is an easy and effective way to evaluate Asian people’s
osteoporosis. Neither OSTA nor QUS can solely achieve the desired sensitivity and
specificity when screening for osteoporosis, but it is a feasible way to combine
both methods. This study aims to explore the use of combining QUS and OSTA to
evaluate the risk of osteoporosis in a community of postmenopausal women.
Methods: From September 2014 to December 2014, bone mineral density of 118
postmenopausal women was measured in Guangzhou communities by quantitative
ultrasound measurement and relative information such as their ages and BMI were
collected through questionnaires. Patients also went through lumbar and dual-en-
ergy X-ray scans. DXA test results were taken as the gold standard of osteoporosis
diagnosis, by drawing an ROC curve, this research evaluates the feasibility of the
joined use of QUS and OSTA score in osteoporosis screening and determine the
appropriate diagnosis point.
Results: When combined use of OSTA and for screening, the regression curve was
fitted as YZ1.688*QUSe0.186*OSTAe3.973. Y was considered to be a predicted
value. Meanwhile, the AUC of ROC drawn by predicted value and DXA screening
result is 0.847, SEZ0.041.
Discussions and Conclusions: Quantitative Ultrasound (QUS) and OSTA score is a
simple and economic method of predicting the incidence of osteoporosis in the
elderly. By setting the QUS and OSTA threshold, it can effectively screen osteopo-
rosis in patients at high risk.
http://dx.doi.org/10.1016/j.jot.2016.06.095411
ESTABLISHMENT OF OSTEOPOROSIS MODEL IN C57/BL6 MICE BY OVARIECTOMY
Yue Ding, Guangtao Fu, Changchuan Li, Shixun Li, Junxiong Qiu
The Memorial Hospital of Sun Yat-sen University, China
Background: To investigate the optimum timing and how long to build the osteo-
porosis model in C57/BL6 mice by ovariectomy (OVX).
Methods: Fifty six-week-old female C57/BL6 mice were divided into ten groups (A-
J). Group A and F underwent BMDmeasurement by DEXA on cranium at eight-weeks-
old and twelve-weeks-old, respectively. The BMD analysis of group B-E was per-
formed at 8 weeks, 10 weeks, 12week, and 14 weeks after the mice underwent
OVX at eight weeks old. The BMD analysis of group G-J was performed at 6 weeks,
8 weeks, 10 week, and 12 weeks after themice underwent OVX at twelve weeks old.
Results: The mean BMD on the cranium of twelve-week-old mice (0.1310.030g/
cm2) was significantly higher than the BMD of eight-week-old mice
(0.1130.042g/cm2) (P<0.05). There was no significant difference between groups
A-E. The mean BMD on the cranium of group F (0.1310.030g/cm2) was signifi-
cantly higher than the BMD of group H (0.1130.014g/cm2) (P<0.05). The BMD
decreased smoothly from H-J (P>0.05).
Discussions and Conclusions: The optimum age to build up the osteoporosis model
in C57/BL6 mice is twelve weeks old and we should wait at least 8 weeks before
the model is established.
http://dx.doi.org/10.1016/j.jot.2016.06.195STIM1 REGULATED OSTEOBLAST DIFFERENTIATION IN THE DEVELOPMENT OF
POSTMENOPAUSAL OSTEOPOROSIS
Yuehu Han, Zhuojing Luo, Liu Yang
Xijing Hospital, the Fourth Military Medical University, China
Introduction: Calcium is required for a number of functions in the body. Past
research has established the strong correlation between calcium homeostasis
and supplementation leading to enhanced bone health in postmenopausal women.
However, calcium supplementation is not without controversy and benefits on skel-
etal health need to be balanced against potential risks. Results of recent clinical
trials indicate that calcium supplementation does not significantly reduce fracture
risk in postmenopausal woman. The underlying mechanisms of this controversy
have not been well defined. Stromal interaction molecule-1(STIM1) is localised in
the endoplasmic reticulum (ER), senses [Ca2+] ER, and activates the Ca
2+ release
activated Ca2+ (CRAC) channel upon store depletion. Recent research found that
CRAC channel plays an essential role in differentiation and function of osteoclasts
and osteoblasts. Here we have investigated the role of STIM1 in the osteogenic dif-
ferentiation of osteoblasts and postmenopausal osteoporosis.
Subjects and methods: BMMSCs were cultured in the presence of osteogenic in-
duction for 14 days after being obtained from postmenopausal osteoporosis pa-
tients. We analysed the Ca2+ concentration and CRAC channel by Fluo-3 staining
before and after osteogenic induction, respectively. STIM1 expression and osteo-
genic differentiation was further evaluated using quantitative real time PCR to
compare expression of STIM1 and osteogenic markers. We conducted knockdown
of one component of the CRAC channel, STIM1 in MC3T3-E1 using stable shRNA
interference. Detection of the osteogenic gene markers, ALP activity, and
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osteogenesis. We next investigated the effects of 17b-estradiol on STIM1.
MC3T3-E1 were cultured in the presence of 17b-estradiol and 17b-estradiol inhib-
itor (ICI) while osteogenic induction was conducted. RT-PCR and Western Blot was
used to detect the expression and mRNA transcript levels. To elucidate the under-
lying mechanism of oestrogen on STIM1, we added an inhibitor of PI3K and mTOR to
determine whether this signalling pathway was involved. To investigate the role of
STIM1 in osteoblast differentiation and osteogenesis regulated by 17b-estradiol,
we compared the osteogenic gene markers, ALP activity, and mineralization ability
between STIM1 knockdown and control group in the presence of 17b-estradiol.
Results: The function of the CRAC channel and osteogenic differentiation of BMMSCs
is decreased in postmenopausal osteoporosis patients. Knockdown of STIM1 weak-
ened the osteogenic differentiation and mineralisation of osteoblasts derived
from MC3T3-E1 dramatically. We found that 17b- E2 can promote the expression
and transcription of STIM1 via the PI3K-mTOR signalling pathway. STIM1 also plays
an essential role in osteogenic differentiation of osteoblasts regulated by oestrogen.
Discussion and Conclusion: In summary, we found that the expression of STIM1 is
decreased due to low activity of PI3K-mTOR signalling pathway, because of the low
level of oestrogen after menopause. The decreased expression of STIM1 affects the
differentiation and bone formation. Our study preliminarily clarified the underlying
mechanism of the role of STIM1 on osteogenesis and bone formation, further studies
areneeded toclarifypotentialmechanismsandprovidenew strategies for treatment.
http://dx.doi.org/10.1016/j.jot.2016.06.202516
CHEMOKINES: A POTENTIAL MOLECULAR LINK BETWEEN CHONDROCYTE
APOPTOSIS AND OSTEOCLAST MIGRATION AND FORMATION FOLLOWING
DEXAMETHASONE THERAPY
Qian Tang
University of South Australia, Australia
Introduction: Glucocorticoid therapy is known to cause growth plate chondrocyte
damage, bone growth arrest, bone resorption, and bone loss, for which themechanisms remain unclear. The current study aims to identify whether apoptotic
chondrocytes secrete factors that may stimulate osteoclast differentiation. It was
hypothesised that dexamethasone (Dex) will induce chondrocyte apoptosis,
causing increased secretion of chemokines with the capacity to promote osteoclast
recruitment and formation.
Subjects and Methods: The current study utilized an in vitro Dex treatment
model in ATDC5 chondrogenic cells and examined treatment effects on molecu-
lar marker expression, induction of apoptosis, and expression of chemokines and
receptors in differentiated Dex-treated chondrocytes. In addition, ability of pro-
moting osteoclast differentiation in RAW264.7 osteoclast precursor cells was
assessed for conditioned media taken from Dex-treated or -untreated
chondrocytes.
Results: In a time course of chondrogenic culture, the increased type II and X
collagen expression suggests the dynamic chondrocyte differentiation. The signif-
icantly enhanced increased density of apoptotic cells as observed by Hoechst dye
staining as well as markedly increased expression level of Fas-L as examined by
real-time quantitative RT-PCR suggests increased chondrocyte apoptosis following
Dex treatment. Meanwhile, chemokine PCR array analysis of Dex-treated or -un-
treated chondrocytes identified up-regulation of various chemokines in treated
chondrocytes. Chemokine SDF-1 was demonstrated to be the chemokine with
the highest induction following treatment, and its induction was also supported
by conformational RT-PCR. Furthermore, the SDF-1 protein level was also
increased as assayed by ELISA in the conditioned medium of Dex-treated chondro-
cytes. Moreover, it was found that conditioned medium from Dex-treated chondro-
cytes was able to stimulate migration of RAW264.7 cells as well as enhance
formation of TRAP-positively stained RAW264.7 cells. In particular, inhibition of
these promoting effects of the conditioned medium by a neutralising antibody
for SDF-1 was also observed.
Discussion and Conclusion: These findings suggest that Dex treatment can cause
apoptosis of chondrocytes and elevated expression of chemokines by apoptotic
chondrocytes, which may be responsible for enhanced osteoclast migration and
formation, serving as a potential molecular link between chondrocyte apoptosis
and osteoclast differentiation.
http://dx.doi.org/10.1016/j.jot.2016.06.203
